Human Cytokine Panel 1 (6-Plex)

Q-Plex™ Product Overview

Product Overview

The Q-Plex Human Cytokine Panel 1 (6-Plex) is a fully quantitative ELISA-based chemiluminescent assay allowing concurrent measurement of six biomarkers or analytes (IL-1β, IL-6, TNFα, IFN-γ, IL-1α, IL-10).

Each kit contains a 96-well plate, with each well featuring the relevant biomarker panel, and all the reagents required to perform testing. Q-Plex plates are built by absorbing six distinct capture antibodies in a defined array to the bottom of each well. Our high-quality reagents help ensure the accuracy of your results.

Using only 25 µl of sample per well, up to 80 samples can be assayed for all six markers in the panel in 2.25 hours. Q-Plex Arrays provide scientists with an easy-to-use and cost-effective means of generating a cytokine profile for each sample.

Q-Plex™ Human Cytokine Panel 1 (6-Plex)

For measurement of IL-1β, IL-6, TNFα, IFN-γ, IL-1α, IL-10

Species: Human
Sample Type: Serum, EDTA/Heparin Plasma
Volume Required per Well: Min 25 µl
Assay Length: 2.25 hours
Specificity: All analytes < 1% intra-panel cross-reactivity
Assay Type: Planar Based Multiplexed ELISA
Detection Method: Chemiluminescent
Multiplex Format: 96-well solid plate
Catalog: #115233HU
Units Calibrator Range LLD
IL-1β pg/ml 10000 - 13.72 10.14
IL-6 pg/ml 3000 - 4.11 3.47
TNFα pg/ml 4000 - 5.49 5.20
IFN-γ pg/ml 8000 - 10.97 4.95
IL-1α pg/ml 4000 - 5.49 5.43
IL-10 pg/ml 3000 - 4.11 4.10
Interleukin 1 beta (IL-1β) is a cytokine involved in pro-inflammatory responses. It is produced by activated macrophages, natural killer cells, monocytes, and neutrophils in response to wounds, infections, or microbial endotoxins and is processed to its active state by caspase 1. It mediates inflammatory responses and plays a role in cell proliferation, apoptosis, and differentiation. IL-1β inflammation within the central nervous system is known to result in pain and hypersensitivity. High levels of IL-1β are associated with autoinflammatory diseases, particularly the group of rare heterozygous dominant diseases known as cryopyrin-associated periodic syndromes, that often affect the skin, joints, eyes, and nervous system. Inhibition of IL-1β treats these diseases and eases symptoms in common conditions such as type 2 diabetes, cardiac failure, gout, and rheumatoid arthritis. Dysregulated IL-1β is associated with tumor formation in a wide variety of cancers.
Interleuken 6 (IL-6) has the capability to behave as both a pro-inflammatory cytokine and an anti-inflammation myokine. As a cytokine, it is secreted by macrophages in response to microbial activity, to regulate the progression of fever through raising the temperature of muscle and fat, as well as crossing the blood-brain barrier to alter the body’s temperature set point in the hypothalamus. It acts through T cells and macrophages fighting infection and causing inflammation. As a myokine, it is released by contracting muscles during exercise, and inhibits the activity of pro-inflammatory agent TNF-alpha, reducing system-wide inflammation. In addition to its functions in the immune system, IL-6 aids in bone remodeling and maintenance by stimulating the production of osteoclasts. Clinically, IL-6 is implicated in the inflammatory and autoimmune symptoms of many diseases, including diabetes, asthma, atherosclerosis, depression, Alzheimer’s disease, rheumatoid arthritis, and many cancers. High levels of IL-6 are common in advanced cancer patients and are correlated with low survival rates. IL-6 has the ability to induce epigenetic modifications of gene transcription in the brain, and these IL-6 modifications are associated with schizophrenia and major depressive disorder.
Tumor necrosis factor alpha (TNFα) is a prototypic ligand of the TNF superfamily. It is a versatile cytokine that plays a central role in inflammation, immune system development, apoptosis, and lipid metabolism. TNFα is an important endogenous pyrogen, its release quickly induces fever. It also causes apoptotic cell death, cachexia, inflammation, and has the ability to inhibit tumorigenesis and viral replication. It is chemoattractive to many immune cells, particularly neutrophils. Cell surface TNFα can induce the lysis of neighboring tumor cells and virus infected cells and has the ability to generate its own downstream cell signaling. It is produced chiefly by activated macrophages, although it is produced in low levels by a wide variety of immune, epithelial, endothelial, and tumor cells such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. TNFα also plays an important role in metabolism, with the ability to induce insulin resistance and regulate appetite through interactions with the hypothalamus. Dysregulation of TNF production has been implicated in a variety of human diseases including Alzheimer’s disease, inflammatory bowel disease, arthritis, cancer, and psoriasis.
Interferon gamma (IFNγ), also known as Type II interferon, is a cytokine that plays a critical role in the innate and adaptive immune systems. It serves as protection against viral infections, as well as some bacterial and protozoal infections, and plays a role in tumor control. It is capable of inhibiting viral replication and works to modulate immunological responses to multiple kinds of pathogens, with effects including promoting natural killer cell activity, activating macrophages to destroy foreign cells, increasing antigen presentation, and inducing the expression of numerous immune defense factors. IFNγ is primarily produced by natural killer and natural killer T cells during the innate immune response and by CD4 and CD8 cytotoxic T lymphocyte effector T cells as part of an adaptive response. It has been shown to halt growth and induce apoptosis in some types of tumors. During pregnancy, IFNγ aids in the remodeling of the uterine wall and placenta to accommodate a zygote.
Interleuken 1 alpha (IL-1α), also known as hematopoietin 1, is a cytokine that plays a role in inflammation, fever, and sepsis. It is produced by macrophages, neutrophils, and endothelial and epithelial cells. In the skin, IL-1α is regularly produced at high levels and helps maintain skin barrier function against pathogens as well as overall skin condition. As part of the immune response, its production is by microbial exposure. It is responsible for releasing inflammatory mediators and acute phase proteins. The severity of inflammation, fever, and sepsis are associated with circulating IL-1α levels. IL-1α inhibitors are a potential target for therapeutics to treat and prevent these conditions as well as mediate skin conditions such as acne. Additionally, IL-1a is part of the pathway that activates tumor necrosis factor-alpha and helps kill some kinds of cancer cells. It also supports stem cell expansion and osteoclast formation following bone marrow transplant.
Interleukin 10 (IL-10) is a class-2 anti-inflammatory cytokine, also known as human cytokine synthesis inhibitory factor (CSIF). It impacts many areas of immunoregulation and inflammation, with numerous pleiotropic effects in the immune system. As an anti-inflammatory, it downregulates MHC class II expression, inhibits the synthesis and activity of many inflammatory cytokines, and reduces co-stimulatory factors on macrophages. It also enhances the release of other anti-inflammatory mediators by monocytes and macrophage, particularly during exercise. It enhances B cell proliferation, differentiation, survival, and antibody production. IL-10 has anti-tumor effects, reducing tumor growth and decreasing metastatic burden in the body. IL-10 deficiency is associated with chronic inflammatory and autoimmune diseases, including multiple sclerosis, Crohn’s disease, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. IL-10 is currently under investigation as a potential therapeutic for many conditions, including cancer treatments and reducing symptoms in inflammatory disorders.


Each kit contains a 96-well plate, featuring the relevant biomarker panel in each well, and all reagents required to perform testing.

Reagents Include:

  • Calibrator
  • Detection Mix
  • Substrate
  • Sample Diluents
  • Streptavidin HRP
  • Wash Buffer

All Quansys Q-Plex™ Multiplex and Singleplex assays require the use of the Q-View™ software to read and interpret the test results. A fully-functional, free trial version of the software is available to download, install, and use to analyze your first kit(s). At the end of the trial period, a purchased license is required to continue the use of the Q-View software.

Q-Plex arrays are developed and optimized to work with Q-View imagers. Quansys does not guarantee the results obtained from other imagers and not all imagers are compatible with Quansys Q-Plex arrays.

Other Equipment Recommendations

As researchers and problem solvers ourselves, we understand the value of sound data. We are proud to be a part of research that can better the world. We value the relationships, partnerships, and friendships that we have built with the people who trust and use our technology. We are committed to building these relationships. You can count on us to answer the phone and take time to thoroughly address questions or concerns about any of our products. In an industry that is reputed for grandiose claims, we trust that our quality standards and our customer service set us apart from the competition. If you’re happy with our products or if you think we can do something better, we hope you will let us know.


365 North 600 West Logan, UT 84321